Other antidiabetics, such as sulfonylureas, alpha-glucosidase inhibitors (AGIs), thiazolidinediones (TZDs), and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been associated with varying levels of cancer risk in LC studies [13]. This evidence concerns the gene DPP4 and cancer.